Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effectiveness, safety, and tolerability of ZP5-9676 for treating soil-transmitted helminthiasis STH infections, including hookworm, Ascaris lumbricoides, and Trichuris trichiura. The study plans to enroll approximately 300 infected participants, including both pediatric and adult individuals living in high prevalence areas, to ensure sufficient numbers of participants with hookworm infections for analysis. Participants will be randomly assigned in a 11 ratio to receive either the active drug ZP5-9676 at a 600 mg dose or a matching placebo. After the study treatment, participants will receive standard of care treatment as applicable. The active treatment is an oral chewable tablet formulation of flubendazole. The study follows a parallel design with two treatment groups. During the study, participants will be assessed for cure rates and egg reduction at 14 days post-treatment. Eligibility includes positive infection confirmed by microscopic examination of fecal samples. Safety and tolerability will be monitored throughout. Participants must comply with study procedures including contraception requirements for females of childbearing potential. The total participation duration includes screening and follow-up visits around the treatment period.